BASKING RIDGE, N.J., Aug. 14, 2013 /PRNewswire/ -- Mylan Specialty L.P., the fully integrated specialty pharmaceutical business of Mylan Inc. (NASDAQ: MYL), today announced it is continuing the EpiPen4Schools ™ program. In its first year, more than 20,000 schools across all 50 states participated in the program that offers four free EpiPen or EpiPen Jr ® (epinephrine) Auto-Injectors to qualifying schools in the U.S. Qualifications include having a valid prescription.
Over the last year, there has been significant legislative movement across the country to improve access to epinephrine, which should encourage more schools to take advantage of the EpiPen4Schools program. The goal of the program is to help schools have ready access to epinephrine auto-injectors in case a person experiences a life-threatening allergic reaction (anaphylaxis) at school. People are encouraged to visit www.EpiPen4Schools.com for more information.
"Educating the public about anaphylaxis preparedness and working to improve access to treatment continues to be an important focus at Mylan, which is why we are pleased to be able to extend EpiPen4Schools," said Heather Bresch, CEO of Mylan. "We hope all schools that have participated in the past will sign up again, and those that haven't yet enrolled in the EpiPen4Schools program will do so quickly, so that EpiPen Auto-Injectors are in place by the start of the 2013 school year."
Anaphylaxis is unpredictable. For those at risk, it is important to be prepared with an anaphylaxis action plan that includes avoiding known allergens, recognizing the signs and symptoms of anaphylaxis, having immediate access to two epinephrine auto-injectors and seeking immediate emergency medical care should anaphylaxis occur. However, accidental exposure to an allergen can still occur and first-time reactions to unknown allergens are a possibility. Schools should also be prepared with an anaphylaxis action plan.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV